Geographic · Total Revenue

Europe — Total Revenue

Moderna Europe — Total Revenue remained flat by 0.0% to $13.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 91.1%, from $149.50M to $13.25M. Over 4 years (FY 2021 to FY 2025), Europe — Total Revenue shows a downward trend with a -70.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ1 2019
Last reportedQ4 2025Feb 20, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates growing market share or successful product adoption in Europe, while a decrease suggests declining demand, pricing pressure, or loss of market exclusivity.

Detailed definition

This metric represents the total gross revenue generated from the sale of products and services within the European geog...

Peer comparison

Comparable to regional revenue reporting by other multinational pharmaceutical and biotech firms, often benchmarked against regional GDP growth and local healthcare spending.

Metric ID: mrna_segment_europe_total_revenue

Historical Data

5 years
 FY'21FY'22FY'23FY'24FY'25
Value$6.85B$6.82B$1.36B$598.00M$53.00M
YoY Change-0.5%-80.1%-55.9%-91.1%
Range$53.00M$6.85B
CAGR-70.3%
Avg YoY Growth-56.9%
Median YoY Growth-68.0%
Current Streak4+ years decline

Frequently Asked Questions

What is Moderna's europe — total revenue?
Moderna (MRNA) reported europe — total revenue of $13.25M in Q4 2025.
How has Moderna's europe — total revenue changed year-over-year?
Moderna's europe — total revenue decreased by 91.1% year-over-year, from $149.50M to $13.25M.
What is the long-term trend for Moderna's europe — total revenue?
Over 4 years (2021 to 2025), Moderna's europe — total revenue has grown at a -70.3% compound annual growth rate (CAGR), from $6.85B to $53.00M.
What does europe — total revenue mean?
The total amount of money earned from sales in the European market.